|
|
|
|
|
Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases |
| HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping |
| Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450003, China |
|
|
|
|
Abstract Objective To investigate the clinical efficacy and prognostic factors of autologous hematopoietic stem cell transplantation (ASCT) for Hodgkin’s lymphoma (HL). Methods We retrospectively analyzed the data of 38 patients with HL who underwent ASCT. Kaplan-Meier and Cox methods were used to analyze the curative effect and prognostic factors after transplantation. Results All 38 transplanted patients obtained hematopoietic reconstitution. The CR rates before and after transplantation were 55.3% and 81.6%, respectively, and the 5-year PFS and OS were 76.1% and 79.0%, respectively. Univariate analysis showed that B symptoms, IPS score, pre-transplant remission status, extranodal invasion, and pretreatment regimen were the factors affecting the prognosis of ASCT in patients with HL. Multivariate analysis showed that B symptom was an independent risk factor affecting 5-year PFS. Conclusion ASCT is effective in the treatment of high-risk, relapsed, and refractory patients with HL. B symptom is an independent risk factor affecting the prognosis of transplantation.
|
| Keywords
Hematopoietic stem cell transplantation
Autologous
Hodgkin’s lymphoma
Prognosis
Curative effect
|
|
|
|
Issue Date: 15 September 2022
|
|
| [1] Momotow J, Borchmann S, Eichenauer DA, et al. Hodgkin<br />
lymphoma-re view on pathogenesis, diagnosis, current and future<br />
treatment approaches for adult patients[J]. J Clin Med, 2021,<br />
10(5): 1125.<br />
[2] Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis, riskstratification,<br />
and management[J]. Am J Hematol, 2020, 95(8):<br />
978-989.<br />
[3] Roerden M, S?kler M, Kanz L, et al. Outcome after autologous<br />
stem cell transplantation in primary refractory or relapsed Hodgkin<br />
lymphoma-a long-term follow-up single center experience[J]. Ann<br />
Hematol, 2020, 99(2): 265-276.<br />
[4] Xie Y, Wang X, Leng X, et al. High-dose chemotherapy followed<br />
by autologous stem cell transplantation for patients with<br />
refractory/relapsed classical Hodgkin lymphoma: A single center<br />
experience from China[J]. Ann Hematol, 2020, 99(3): 549-555.<br />
[5] Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcome of children<br />
and adolescents with relapsed Hodgkin lymphoma treated with<br />
high-dose therapy and autologous stem cell transplantation: The<br />
Memorial Sloan Kettering Cancer Center experience[J]. Leuk<br />
Lymphoma, 2018, 59(8): 1861-1870.<br />
[6] Zou DM, Zhou DB, Zhang Y, et al. Clinical characteristics and<br />
prognostic factors in Chinese patients with classical Hodgkin's<br />
lymphoma involving extranodal sites: A retrospective singlecenter[<br />
J]. Hematology, 2019, 24(1): 661-668.<br />
[7] Singer S, Dean R, Zhao Q, et al. BEAM versus BUCYVP16<br />
conditioning before autologous hematopoietic stem cell transplant<br />
in patients with Hodgkin lymphoma[J]. Biol Blood Marrow<br />
Transplant, 2019, 25(6):1107-1115.<br />
[8] 喻凤宽, 周健, 李玉富, 等. BEAC预处理自体造血干细胞移<br />
植治疗淋巴瘤的疗效观察[J]. 肿瘤防治研究, 2011, 38(11):<br />
1324-1325, 1340. [Yu FK, Zhou J, Li YF, et al. Observation of<br />
the effect of BEAC preconditioning on autologous hematopoietic<br />
stem cell transplantation in lymphoma[J]. Zhong Liu Fang Zhi<br />
Yan Jiu, 2011, 38(11): 1324-1325, 1340.]<br />
[9] Halacoglu A, Serefhanoglu S. A retrospective comparison of<br />
mitoxantrone-melphalan and BEAM conditioning regimens<br />
before autologous hematopoietic stem cell transplantation in<br />
relapsed/refractory lymphoma patients[J]. Indian J Hematol Blood<br />
Transfus, 2022, 38(1): 92-98.<br />
[10] Hasenclever D, Diehl V. A prognostic score for advanced<br />
Hodgkin's disease. international prognostic factors project on<br />
advanced Hodgkin's disease[J]. N Engl J Med, 1998, 339(21):<br />
1506-1514.<br />
[11] Diefenbach CS, Li H, Hong F, et al. Evaluation of the International<br />
Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3)<br />
for advanced Hodgkin lymphoma in the modern era[J]. Br J<br />
Haematol, 2015, 171(4): 530-538.<br />
[12] O'Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus<br />
bendamustine in relapsed or refractory Hodgkin’s lymphoma: An<br />
international, multicentre, single-arm, phase 1-2 trial[J]. Lancet<br />
Oncol, 2018, 19(2): 257-266.<br />
[13] Crump M. Time to change direction in the treatment of relapsed<br />
Hodgkin lymphoma? [J]. J Clin Oncol, 2021, 39(2): 97-99.<br />
[14] Andrade-Gonzalez X, Ansell SM. Novel therapies in the treatment<br />
of Hodgkin lymphoma[J]. Curr Treat Options Oncol, 2021, 22(5):<br />
42. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
